London Jackson
Primary Care · Springville, UTNPI 1902416795
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,169 of the $22,294 with a category attached, or 77.0%. AbbVie accounts for 90.8% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $19,011, more than ten times the $359 reported in 2021. Among primary care clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $79.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Pfizer$327
- Teva Pharmaceuticals USA, Inc.$286
- Lilly USA, LLC$271
- Axsome Therapeutics, Inc.$168
- Boehringer Ingelheim$160
- plus $845 from 23 others
What the payments were for
- Speaking & faculty fees$17,16977%
- Travel & lodging$5643%
- Food & beverage$4,56120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 151 | $20,237 |
| Pfizer | 20 | $327 |
| Teva Pharmaceuticals USA, Inc. | 34 | $286 |
| Lilly USA, LLC | 17 | $271 |
| Axsome Therapeutics, Inc. | 4 | $168 |
| Boehringer Ingelheim | 8 | $160 |
| Lundbeck LLC | 6 | $109 |
| Idorsia Pharmaceuticals US Inc | 5 | $80 |
| Amgen | 5 | $78 |
| Biohaven Pharmaceuticals, Inc. | 1 | $73 |
| Bayer | 4 | $68 |
| Viiv Healthcare Company | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Merck | 2 | $36 |
| Boston Scientific | 2 | $36 |
| Novo Nordisk | 2 | $32 |
| Upsher-smith Laboratories LLC | 2 | $28 |
| Dynavax Technologies Corporation | 2 | $27 |
| GSK | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,294 in reported general payments places this provider in the 95th percentile of 60 primary care providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 17 | $12,917 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,508 |
| Gabapentin | 21 | $344 |
| Amitriptyline Hcl | 18 | $208 |
| Propranolol Hcl | 17 | $202 |
| RizatriptanRizatriptan Benzoate | 20 | $187 |
| Omeprazole | 13 | $133 |
| Levothyroxine Sodium | 14 | $129 |
| Topiramate | 11 | $67 |
| Fluoxetine Hcl | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $28 | $6711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 primary care providers in Utah.
Other primary care in Springville
- Emily DunnSpringville$924
- Tyler HobbsProvo$15K
- Jeffrey WalshBountiful$15K
- Marcella RowleyRiverton$13K
- Elizabeth WillmoreRiverton$6K
- Dustin ThompsonLayton$6K
- Catherine CoatesSalt Lake City$5K
- Liana KinikiniWest Jordan$4K
- Stacey LakeHolladay$3K
- Madeleine RupertSalt Lake City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.